PAVM · XBRL financial data

PAVmed financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (PAVM's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	—	—	—	2,500	3,000	—
Revenue from contracts with customers	—	500	377	2,452	2,995	71
Cost of revenue	—	585	3,614	6,420	4,840	218
Gross profit	—	(85)	—	—	—	—
Research and development	10,963	19,847	25,547	14,276	5,932	4,492
General and administrative	12,388	25,566	41,041	30,947	24,524	16,250
Total operating expenses	23,351	54,308	—	—	—	—
Operating income (loss)	(23,351)	(54,393)	(90,927)	(68,795)	(44,487)	(21,806)
Interest income	—	—	—	—	254	29
Interest expense	53,000	—	1,272	589	45	21
Other income (expense)	(12,537)	(1,733)	(12,311)	(10,468)	—	—
Income tax expense (benefit)	—	—	—	—	0	0
Net income (loss)	(34,276)	(50,347)	(88,983)	(64,175)	39,791	401
Earnings per share, basic USD per share	—	(0.65)	(1.00)	(9.16)	3.30	(5.63)
Earnings per share, diluted USD per share	—	—	(15.03)	(9.16)	0.50	(5.63)
Weighted average shares, basic thousands of shares	—	77,516	89,076	7,232	9,672	670
Weighted average shares, diluted thousands of shares	—	—	5,938	7,232	65,292	670

† Share count changed about 1/11 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (PAVM's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	17,256	77,258	39,744	19,639	1,185	1,538
Accounts receivable	—	200	17	61	18	—
Inventory	—	—	111	278	—	—
Prepaid and other current assets	1,685	5,179	4,165	4,520	961	1,004
Total current assets	18,941	82,637	43,926	24,498	2,164	2,557
Property and equipment, net	82	1,585	2,451	1,783	151	77
Right-of-use asset	—	—	3,037	4,267	2,500	2,002
Total assets	19,778	86,976	53,980	33,119	30,660	38,812
Accounts payable	2,966	3,299	2,704	1,786	657	678
Accrued liabilities	2,325	4,259	3,705	6,626	5,176	2,486
Total current liabilities	—	7,558	41,200	54,177	35,446	14,837
Lease liability, non-current	—	—	1,846	2,960	2,247	1,675
Total liabilities	20,251	7,558	43,046	57,137	37,693	16,512
Accumulated deficit	(88,275)	(138,910)	(228,169)	(294,433)	(254,965)	(258,731)
Total stockholders' equity	1,896	61,666	(9,681)	(53,831)	(2,495)	33,967
Total liabilities and equity	19,778	86,976	53,980	33,119	30,660	38,812
Common shares outstanding (cover page) thousands of shares	82,461	87,667	98,420	9,172	11,523	6,383

† Share count changed about 1/11 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (PAVM's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(34,276)	(50,347)	(88,983)	(64,175)	39,791	401
Stock-based compensation	2,044	15,009	19,532	11,139	6,449	1,707
Depreciation and amortization	—	226	2,457	2,932	1,198	105
Net cash from operating activities	(21,914)	(40,591)	(70,985)	(52,036)	(33,554)	(5,206)
Purchases of property and equipment	55	1,469	1,540	242	55	31
Net cash from investing activities	(55)	(3,716)	(4,740)	758	(16,184)	(31)
Proceeds from issuing common stock	16,032	55,016	79	1,533	1,598	—
Net cash from financing activities	33,006	104,309	38,211	31,173	31,284	5,590
Net change in cash	11,037	60,002	(37,514)	(20,105)	(18,454)	353

† Share count changed about 1/11 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
PAVmed	3,784	33	(2,663)*	8.0M	1.4 quarters	Q2 FY26 10-QJun 30, 2026
Intelligent Bio Solutions	3,992	1,146*	(3,182)*	3.0M	1.3 quarters	Q4 FY26 10-KJun 30, 2026
PetVivo Holdings	123	338	(966)	38.0M	0.1 quarters	Q1 FY27 10-QJun 30, 2026
Lyra Therapeutics	15,893	7*	(6,066)*	1.8M	2.6 quarters	Q4 FY25 10-KDec 31, 2025
Nexgel	1,706	3,686	(2,197)*	9.7M	0.8 quarters	Q2 FY26 10-QJun 30, 2026
Envoy Medical	19,679	51	(5,456)*	77.2M	3.6 quarters	Q2 FY26 10-QJun 30, 2026
VASO	38,291	not reported	17,444*	176.0M	—	Q2 FY26 10-QJun 30, 2026
Guided Therapeutics	12	0	(319)*	96.5M	0.0 quarters	Q2 FY26 10-QJun 30, 2026
Biotricity	467	4,277	507	19.9M	—	Q1 FY27 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.